Please login to the form below

Not currently logged in
Email:
Password:

Forest diabetes drug study fails

Forest's neuropathic pain drug, radiprodil, has missed its primary endpoint in a phase II study

Radiprodil (RGH-896), in development by Forest Laboratories for the treatment of neuropathic pain associated with diabetic peripheral neuropathy missed its primary endpoint in a phase II study compared to placebo.

Forest and its partner on the drug, Gedeon Richter, said that they have not yet made a determination about whether to continue development of the product, but will do so in the coming weeks after reviewing the complete study database.

The drug is part of a wider development partnership signed between Forest and Budapest, Hungary-based Richter in 2005. The agreement gave Forest exclusive rights to the product in the US and Canada in return for undisclosed upfront and milestone payments, research funding and royalties.

Radiprodil targets a specific portion of the NMDA receptor that may be involved in the transmission of pain, an approach that the companies hoped would yield improvements in efficacy and the side effect profile compared to currently available treatments.

However, top-line results from the phase II dose-response trial failed to show statistically significant or clinically meaningful reductions in mean daily pain scores compared to placebo, which was the study's primary endpoint. The 14-week study enrolled about 450 patients.

Forest and Richter are also developing radiprodil for other chronic neuropathic pain conditions.

29th June 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mind+Matter

We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...